Driven by aging population, increasing incidence of neurological disorders, and growing number of cases with urinary incontinence, the rechargeable sacral nerve stimulators (SNS) market in Australia is expected to grow at a compound annual growth rate (CAGR) of 3% through 2033, forecasts GlobalData, a leading data, and analytics company.

GlobalData’s report, “Neuromodulation Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033,” reveals that Australia accounts for around 30% of the Asia-Pacific neuromodulation market in 2024, driven by the growing demand for advanced neuromodulation devices.

The recent regulatory approval of the Axonics R20 rechargeable sacral neuromodulation (SNM) system in Australia marked a significant development in the SNS market. With an extended battery life requiring fewer recharges, the R20 offers a long-lasting solution that improves patient convenience. This approval highlights the growing adoption of advanced neuromodulation devices in Australia, setting the stage for market growth in the coming years.

Jyoti Sharma, Medical Devices Analyst at GlobalData, comments: “Rechargeable sacral neuromodulation devices represent a key advancement in neuromodulation space. Their extended battery life and smaller size compared to the non-rechargeable systems provide better convenience and comfort for patients. The longer battery life also reduces the need for frequent replacements, lowering healthcare costs and improving patient satisfaction.”

With sales of the R20 expected to commence in November 2024, along with the recent approval of its F15 recharge-free system, Axonics is well-positioned to strengthen its footprint in Australia’s expanding neuromodulation market. Such advancements will enhance treatment options for patients struggling with incontinence and significantly improve their overall quality of life.

Sharma concludes: “The growing adoption of novel neuromodulation therapies promises to improve patient outcomes and significantly enhance overall well-being. As the market continues to evolve, it will offer significant opportunities for further advancements in treatment options.”